FUJIFILM Diosynth Biotechnologies’ Post

🚨 𝐏𝐟𝐢𝐳𝐞𝐫 𝐥𝐚𝐧𝐝𝐬 𝐧𝐞𝐰 𝐠𝐞𝐧𝐞 𝐭𝐡𝐞𝐫𝐚𝐩𝐲 𝐚𝐩𝐩𝐫𝐨𝐯𝐚𝐥! The European Commission has officially granted Pfizer's DURVEQTIX gene therapy conditional marketing authorisation for the treatment of severe and moderately severe haemophilia B in adults. ➡️ The approval is based on the Phase 3 BENEGENE-2 study, which showed a significant reduction in the annualised bleed rate (ABR) compared to standard prophylactic factor IX infusions. DURVEQTIX demonstrated a median ABR of zero, suggesting long-term bleed protection and reduced treatment burden. The therapy was generally well-tolerated, with manageable increases in liver enzymes as the most common adverse reaction. The authorisation covers all EU member states, Iceland, Liechtenstein, and Norway, following similar approvals in the U.S. and Canada. Congratulations all! #genetherapy #cellandgenetherapy #biotech #CGTweekly

🚀 Cyclodextrins: New Horizons in Gene Delivery 🧬 In gene therapy, safety and efficiency are paramount. Cyclodextrins, cyclic oligosaccharides derived from starch, are emerging as promising non-viral nanocarriers for genetic material. 🔬 Key Benefits: Biocompatibility: Low toxicity, minimal adverse reactions. Versatility: Efficiently carries DNA, RNA, and siRNA. Controlled Release: Ensures targeted, prolonged therapeutic effects. 🚧 Challenges: Improving transfection efficiency and in vivo performance remains a focus. 🔍 GENEGUT Project: Our Horizon 2020 grant project aims to develop tools for delivering oligonucleotides to treat Crohn's disease. Cyclodextrins offer a safer, versatile alternative to viral vectors, potentially revolutionizing gene therapy. #GeneTherapy #Cyclodextrins #Biotech #Healthcare #GENEGUT

🧬 Faced with the challenge to reliably synthesize and produce complex plasmid DNAs used in the production of viral vectors for gene therapy, Novel Biotechnology submitted 51 UTR sequences for complexity screening to three commonly used DNA synthesis vendors, as well as to Ansa. As they reported in this poster, the majority of the sequences were rejected outright by most vendors, but 100% were accepted for synthesis by Ansa. "Here we have shown how innovations in DNA synthesis and assembly enable the routine production of plasmid designs that would have been difficult, if not impossible, to generate using conventional techniques. These innovations include the use of Ansa’s enzymatic DNA synthesis platform in conjunction with Novel Bio’s in-house workflows for plasmid DNA production. The use of these technologies enabled us to seamlessly deliver on a complicated gene therapy project. Without this capability, this project would have become considerably more complex and costly." Thanks for sharing this success story, Novel Biotechnology Inc.! Interested in putting our #complexDNA synthesis services to the test on your project? Learn how to join our Early Access Program: https://lnkd.in/grMhxgfN #DNAsynthesis #longDNA #Ansamers #biotech #synbio #SyntheticDNA #DNAInnovation #complexDNA #customDNA #AnsamerAnswers

26% of U.S. gene therapy patents belong to the top 10 assignees. Discover how University of Pennsylvania, Immatics, University of California and CRISPR Therapeutics are leading gene therapy innovation. Learn more in our latest patent landscape report. ⬇ #GeneTherapy #Biotech #Innovation #Patents

Don't miss OmniBRx Biotechnologies Pvt Ltd at the 9th Annual Cell and Gene Therapy Symposium in Vellore!  Let's discuss how we can accelerate your research and development in #CellandGeneTherapy #Bioprocess #viralvectors #upstream #bioreactor #biotechnology

Cell & gene therapy (C&GT) manufacturing is expensive. Licensing commercial cell lines for manufacturing can be a significant cost driver for C&GT producers. While out-of-the-box commercial cell lines potentially decrease time to market, their cost remains a concern. Consequently, several gene therapy producers are developing their own production cell lines. However, the cost-effectiveness of cell line development depends on sufficient improvement in output to compensate for development costs. Strategies complementing cell line development with reagent optimization have the potential to accelerate development times and improve the likelihood of success, for example by obtaining higher yield from sub-optimal production clones. #biotechnology #innovation #genetherapy #biomanufacturing  

Take a peek into a riveting report that illuminates revolutionary breakthroughs and emerging technologies, carving the path for the future of Cell and Gene Therapy! 🚀✨ https://lnkd.in/dmJRSBWc #GeneTherapyRevolution #FutureOfMedicine

#geneediting Exciting News for the Biotech Community! 🧬 Cyagen Offers Cutting-Edge Custom Gene Editing Services! Are you in need of precise and reliable gene editing services for your research or biotech development? Look no further! Cyagen provides a comprehensive range of custom gene editing services, including gene knockouts, knock-ins, point mutations, overexpression, and shRNA interference. Whether for basic gene function studies, drug screening, or gene therapy, Cyagen has got you covered. ✨ What's more, for a limited time, Cyagen is offering a special discount on its gene editing services if you order by December 31st, 2024. ⏰ Take advantage of this promotion to advance your research and development projects! Key Features: ✅ Flexible project types and deliverables tailored to your specific needs ✅ Fast turnaround times, with some services available in as little as 6 weeks ✅ Professional project management and Ph.D.-provided technical support available 24/7 ✅ Strict quality control to ensure the highest standards in deliverables Explore the full range of services and popular cell lines available for gene editing: https://lnkd.in/g_KPEmi5 Don't miss out on this exceptional opportunity to elevate your research and development endeavors. Contact us today and unlock the potential of custom gene editing in advancing your scientific pursuits! #genetherapy #Biotech #ResearchAndDevelopment #Cyagen #CustomGeneEditingServices #ScienceAndInnovation #biosciences #biotechnology #biology #scienceandtechnology

Don't forget to join us today at 3pm GMT / 4pm CET /10am EST for the first webinar in our 3 part series on CRISPR and Gene Editing ONLINE. If you can't make it you can still register to catch up on-demand: https://lnkd.in/dA9KycdX   Today, we'll be discussing advances in gene editing systems. We'll be highlighting their applications and benefits and discussing the future of gene editing technologies, both from a technological standpoint and in relation to future therapeutics. Talk 1: Precise Transcript Targeting by CRISPR-Csm Complexes David Colognori, Post-Doctoral Associate, Doudna Lab, UC Berkeley    Talk 2: PRCISR CRISPR: Vivlion’s CRISPR-enabled PCR-free discovery platform   Martin Wegner, Head of R&D, Vivlion GmbH    Talk 3: Precise and Versatile Genome Engineering with Prime Editing  Andrew Anzalone, Head of the Prime Editing Platform and Scientific Co-Founder, Prime Medicine, Inc. #CRISPR #geneediting

🔬 Are you Struggling to achieve desired results in Cell and Gene Therapy, Viral Vector, and vaccine manufacturing using adherent or suspension cell culture bioprocessing platforms? Is troubleshooting issues and maintaining consistent product quality becoming a challenge? OmniBRx has the solution for you! Join Anandprakash Joshi at VIROCON 2023, organized by ICAR- National Research Centre for Banana - India and the Indian Virological Society, to explore our innovative platform. With OmniBRx, you can overcome troubleshooting issues and ensure consistent product quality. Our Adherent solutions (CellBRx and SeedBRx-IST) and Suspension solutions (MiniBRx and PerfBRx) are complemented by groundbreaking automation options. Imagine achieving efficient, scalable, and affordable bioprocessing without breaking the bank. OmniBRx makes this a reality. Let's collaborate and innovate together to overcome your bioprocessing challenges! See you at the conference! 📅🤝 #Biotechexpo #biotechnology #virology #vaccinedevelopment #bioprocessing